STRIVE-02: A first-in-human phase 1 trial of systemic B7H3 CAR T cells for children and young adults with relapsed/refractory solid tumors.
Navin Pinto(Seattle Children's Hospital), Julie R. Park(Seattle Children's Hospital), Ashley Wilson(Center for Infectious Disease Research), Nicholas A. Vitanza(Seattle Children's Hospital), Catherine M. Albert(Seattle Children's Hospital), Stephanie Rawlings-Rhea(Seattle Children's Hospital), Wenjun Huang(Chengdu Research Base of Giant Panda Breeding), Prabha Narayanaswany(Seattle Children's Hospital), Rebecca Gardner(Seattle Children's Hospital), Kristy Seidel(Fred Hutch Cancer Center), Mallory Taylor(Center for Cancer and Blood Disorders), Christopher Brown, Michael C. Jensen(Seattle Children's Hospital), Vicky Wu(Fred Hutch Cancer Center), Rimas J. Orentas(Capital Caring)
Cited by 27
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
|Blood|2017|1.1k
Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
|Clinical Cancer Research|2015|754